Humana Inc. (HUM) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Healthcare Plans
EV/EBITDA
↑
16.83
+3% vs avg
5yr avg: 16.31
30Y Low0.5·High17.4
P/FCF
↑
78.87
↑+99% vs avg
5yr avg: 39.72
30Y Low4.6·High82.5
P/B Ratio
↓
1.68
↓-44% vs avg
5yr avg: 3.01
30Y Low1.1·High4.2
ROE
↓
7.0%
↑-49% vs avg
5yr avg: 13.5%
30Y Low-26%·High26%
Debt/EBITDA
↑
5.68
↑+48% vs avg
5yr avg: 3.83
30Y Low0.0·High5.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
HUM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Humana Inc. trades at 25.0x earnings, 6% above its 5-year average of 23.6x, sitting at the 82nd percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a premium of 13%. On a free-cash-flow basis, the stock trades at 78.9x P/FCF, 99% above the 5-year average of 39.7x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $29.6B | $30.9B | $30.7B | $57.0B | $65.1B | $60.0B | $54.6B | $49.4B | $39.6B | $36.1B | $30.8B |
| Enterprise Value | $38.3B | $39.7B | $40.7B | $64.5B | $71.8B | $69.9B | $57.0B | $51.4B | $43.4B | $37.0B | $31.0B |
| P/E Ratio → | 25.03 | 26.03 | 25.42 | 22.89 | 23.20 | 20.46 | 16.21 | 18.23 | 23.56 | 14.76 | 50.13 |
| P/S Ratio | 0.23 | 0.24 | 0.26 | 0.54 | 0.70 | 0.72 | 0.71 | 0.76 | 0.70 | 0.67 | 0.57 |
| P/B Ratio | 1.68 | 1.74 | 1.86 | 3.49 | 4.24 | 3.73 | 3.98 | 4.10 | 3.90 | 3.67 | 2.88 |
| P/FCF | 78.87 | 82.53 | 12.83 | 19.14 | 18.87 | 65.24 | 11.67 | 10.86 | 25.40 | 10.25 | 21.85 |
| P/OCF | 32.11 | 33.60 | 10.34 | 14.31 | 14.19 | 26.53 | 9.68 | 9.35 | 18.25 | 8.92 | 15.90 |
P/E links to full P/E history page with 30-year chart
HUM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Humana Inc.'s enterprise value stands at 16.8x EBITDA, roughly in line with its 5-year average of 16.3x. The Healthcare sector median is 14.1x, placing the stock at a 19% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.31 | 0.35 | 0.61 | 0.77 | 0.84 | 0.74 | 0.79 | 0.76 | 0.69 | 0.57 |
| EV / EBITDA | 16.83 | 17.43 | 15.69 | 15.23 | 16.28 | 16.91 | 10.78 | 12.72 | 16.63 | 9.71 | 14.06 |
| EV / EBIT | 26.37 | 19.04 | 17.80 | 16.93 | 18.11 | 18.65 | 11.51 | 13.86 | 18.92 | 7.79 | 14.06 |
| EV / FCF | — | 105.82 | 17.02 | 21.68 | 20.81 | 75.93 | 12.20 | 11.31 | 27.79 | 10.49 | 22.01 |
HUM Profitability
Margins and return-on-capital ratios measuring operating efficiency
Humana Inc. earns an operating margin of 1.1%. Operating margins have compressed from 3.1% to 1.1% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 7.0% is modest. ROIC of 4.1% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 14.5% | 14.5% | 14.6% | 17.0% | 18.5% | 17.3% | 20.3% | 17.2% | 19.7% | 13.2% | 14.3% |
| Operating Margin | 1.1% | 1.1% | 1.4% | 3.1% | 3.8% | 4.1% | 6.1% | 5.3% | 3.6% | 6.2% | 3.2% |
| Net Profit Margin | 0.9% | 0.9% | 1.0% | 2.3% | 3.0% | 3.5% | 4.4% | 4.2% | 3.0% | 4.6% | 1.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.0% | 7.0% | 7.4% | 15.7% | 17.8% | 19.7% | 26.1% | 24.4% | 16.8% | 23.9% | 5.8% |
| ROA | 2.5% | 2.5% | 2.6% | 5.5% | 6.3% | 7.3% | 10.5% | 10.0% | 6.5% | 9.3% | 2.4% |
| ROIC | 4.1% | 4.1% | 4.8% | 10.8% | 11.1% | 12.2% | 23.1% | 18.6% | 12.6% | 23.1% | 11.5% |
| ROCE | 4.0% | 4.0% | 4.6% | 9.9% | 10.7% | 11.3% | 19.3% | 16.9% | 10.1% | 15.6% | 8.7% |
HUM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Humana Inc. carries a Debt/EBITDA ratio of 5.7x, which is highly leveraged (82% above the sector average of 3.1x). Net debt stands at $8.7B ($12.9B total debt minus $4.2B cash). Interest coverage of 3.3x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.73 | 0.73 | 0.75 | 0.75 | 0.76 | 0.82 | 0.52 | 0.51 | 0.60 | 0.50 | 0.38 |
| Debt / EBITDA | 5.68 | 5.68 | 4.72 | 2.90 | 2.67 | 3.20 | 1.35 | 1.51 | 2.33 | 1.29 | 1.85 |
| Net Debt / Equity | — | 0.49 | 0.61 | 0.46 | 0.44 | 0.61 | 0.18 | 0.17 | 0.37 | 0.09 | 0.02 |
| Net Debt / EBITDA | 3.84 | 3.84 | 3.87 | 1.79 | 1.52 | 2.38 | 0.47 | 0.51 | 1.43 | 0.23 | 0.10 |
| Debt / FCF | — | 23.30 | 4.20 | 2.54 | 1.94 | 10.69 | 0.53 | 0.45 | 2.39 | 0.25 | 0.15 |
| Interest Coverage | 3.30 | 3.30 | 3.47 | 7.73 | 9.89 | 11.49 | 17.52 | 15.34 | 10.51 | 19.62 | 11.67 |
HUM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.72x is below 1.0, meaning current liabilities exceed current assets — though the company's $4.2B cash position helps mitigate short-term liquidity concerns. The current ratio has improved from 0.56x to 0.72x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.72 | 0.72 | 0.44 | 0.56 | 0.58 | 0.50 | 0.65 | 0.75 | 0.51 | 1.12 | 0.86 |
| Quick Ratio | 0.72 | 0.72 | 0.44 | 0.56 | 0.58 | 0.50 | 0.65 | 0.75 | 0.51 | 1.12 | 0.86 |
| Cash Ratio | 0.41 | 0.41 | 0.20 | 0.39 | 0.44 | 0.32 | 0.52 | 0.60 | 0.36 | 0.92 | 0.71 |
| Asset Turnover | — | 2.66 | 2.54 | 2.27 | 2.13 | 1.87 | 2.20 | 2.24 | 2.25 | 2.02 | 2.11 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
HUM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Humana Inc. returns 2.0% to shareholders annually — split between a 1.4% dividend yield and 0.5% buyback yield. The payout ratio of 36.2% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 4.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.4% | 1.4% | 1.4% | 0.8% | 0.6% | 0.6% | 0.6% | 0.6% | 0.7% | 0.6% | 0.6% |
| Payout Ratio | 36.2% | 36.2% | 35.7% | 17.3% | 14.0% | 12.1% | 9.6% | 10.7% | 15.7% | 9.0% | 28.8% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.0% | 3.8% | 3.9% | 4.4% | 4.3% | 4.9% | 6.2% | 5.5% | 4.2% | 6.8% | 2.0% |
| FCF Yield | 1.3% | 1.2% | 7.8% | 5.2% | 5.3% | 1.5% | 8.6% | 9.2% | 3.9% | 9.8% | 4.6% |
| Buyback Yield | 0.5% | 0.5% | 2.7% | 2.8% | 3.2% | 0.1% | 3.3% | 2.2% | 2.7% | 9.3% | 0.3% |
| Total Shareholder Yield | 2.0% | 1.9% | 4.1% | 3.5% | 3.8% | 0.7% | 3.9% | 2.8% | 3.4% | 9.9% | 0.9% |
| Shares Outstanding | — | $121M | $121M | $124M | $127M | $129M | $133M | $135M | $138M | $146M | $151M |
Peer Comparison
Compare HUM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 HUMYou | $30B | 25.0 | 16.8 | 78.9 | 14.5% | 1.1% | 7.0% | 4.1% | 5.7 |
 UNH | $333B | 27.8 | 16.6 | 20.7 | 18.5% | 4.2% | 11.8% | 9.2% | 3.4 |
 CVS | $110B | 62.5 | 13.0 | 14.1 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 |
 ELV | $81B | 14.9 | 10.9 | 25.6 | 25.6% | 4.1% | 13.3% | 9.1% | 3.4 |
 CNC | $27B | -4.1 | — | 6.3 | 12.2% | -3.9% | -28.7% | -21.6% | — |
 MOH | $10B | 22.1 | 10.2 | — | 9.0% | 1.7% | 11.0% | 17.4% | 4.0 |
 ALHC | $4B | -4902.7 | 76.6 | 32.8 | 12.4% | 0.4% | -0.5% | — | 7.5 |
 OSCR | $5B | -11.7 | — | 4.9 | 14.4% | -3.4% | -44.4% | — | — |
 CLOV | $1B | -15.8 | — | — | 103.6% | -4.4% | -26.3% | -34.0% | — |
 BHVN | $1B | -1.5 | — | — | — | — | -310.8% | -242.1% | — |
 ACGL | $34B | 8.1 | 6.9 | 5.5 | 37.2% | 25.0% | 19.5% | 15.4% | 0.5 |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Full HUM Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See HUM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HUM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HUM vs UNH
Side-by-side business, growth, and profitability comparison vs UnitedHealth Group Incorporated.
Start ComparisonHUM — Frequently Asked Questions
Quick answers to the most common questions about buying HUM stock.
What is Humana Inc.'s P/E ratio?
Humana Inc.'s current P/E ratio is 25.0x. The historical average is 19.2x. This places it at the 82th percentile of its historical range.
What is Humana Inc.'s EV/EBITDA?
Humana Inc.'s current EV/EBITDA is 16.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 9.6x.
What is Humana Inc.'s ROE?
Humana Inc.'s return on equity (ROE) is 7.0%. The historical average is 13.0%.
Is HUM stock overvalued?
Based on historical data, Humana Inc. is trading at a P/E of 25.0x. This is at the 82th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Humana Inc.'s dividend yield?
Humana Inc.'s current dividend yield is 1.44% with a payout ratio of 36.2%.
What are Humana Inc.'s profit margins?
Humana Inc. has 14.5% gross margin and 1.1% operating margin.
How much debt does Humana Inc. have?
Humana Inc.'s Debt/EBITDA ratio is 5.7x, indicating high leverage. A ratio above 4x may signal elevated financial risk.